Ables, Iannone, Moore & Associates, Inc. Amgen Inc Transaction History
Ables, Iannone, Moore & Associates, Inc.
- $162 Billion
- Q4 2024
A detailed history of Ables, Iannone, Moore & Associates, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Ables, Iannone, Moore & Associates, Inc. holds 3,365 shares of AMGN stock, worth $1.07 Million. This represents 0.54% of its overall portfolio holdings.
Number of Shares
3,365
Previous 3,364
0.03%
Holding current value
$1.07 Million
Previous $1.08 Billion
19.11%
% of portfolio
0.54%
Previous 0.7%
Shares
3 transactions
Others Institutions Holding AMGN
# of Institutions
3,172Shares Held
419MCall Options Held
8.25MPut Options Held
6.39M-
Vanguard Group Inc Valley Forge, PA52.7MShares$16.7 Billion0.25% of portfolio
-
Black Rock Inc. New York, NY46MShares$14.6 Billion0.33% of portfolio
-
State Street Corp Boston, MA29.4MShares$9.32 Billion0.31% of portfolio
-
Morgan Stanley New York, NY14.6MShares$4.61 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA13.2MShares$4.18 Billion0.65% of portfolio
About AMGEN INC
- Ticker AMGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 534,931,008
- Market Cap $169B
- Description
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...